Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
232.32
-9.47 (-3.92%)
At close: Apr 28, 2026, 4:00 PM EDT
232.33
+0.01 (0.00%)
After-hours: Apr 28, 2026, 5:27 PM EDT
Ligand Pharmaceuticals Employees
Ligand Pharmaceuticals had 47 employees as of December 31, 2025. The number of employees decreased by 21 or -30.88% compared to the previous year.
Employees
47
Change (1Y)
-21
Growth (1Y)
-30.88%
Revenue / Employee
$5,703,979
Profits / Employee
$2,647,936
Market Cap
4.66B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Caris Life Sciences | 1,846 |
| Apellis Pharmaceuticals | 739 |
| Corcept Therapeutics | 730 |
| Amicus Therapeutics | 511 |
| TG Therapeutics | 399 |
| CRISPR Therapeutics AG | 393 |
| Xenon Pharmaceuticals | 370 |
LGND News
- 1 day ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation - PRNewsWire
- 1 day ago - Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million - Benzinga
- 1 day ago - Ligand Pharma to buy fellow biotech royalty rights buyer XOMA for $739 million - Reuters
- 1 day ago - Ligand Pharmaceuticals Transcript: M&A announcement - Transcripts
- 1 day ago - Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator - GlobeNewsWire
- 1 day ago - Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million - WSJ
- 6 days ago - Coave Therapeutics to present two posters at ARVO 2026, on first-in-class ligand-conjugated suprachoroidal vector and lead gene therapy program - GlobeNewsWire
- 6 days ago - Ligand to Report First Quarter 2026 Financial Results on May 7, 2026 - GlobeNewsWire